Key Takeaways:
- Azenta reported Q3 EPS of $0.16, beating the $0.1161 consensus estimate.
- Revenue reached $161.2M, topping the $152.3M analyst forecast by 5.9%.
- Both top and bottom lines exceeded expectations for fiscal Q3 2026.
Back
Azenta beats Q3 estimates with $0.16 EPS on $161.2M revenue
Azenta reported fiscal Q3 revenue of $161.2 million, beating the $152.3 million consensus estimate, with EPS of $0.16 topping the $0.1161 forecast.
The $8.9 million revenue beat represents a 5.9 percent upside over analyst expectations, while EPS came in $0.0439 above consensus. The company, which provides sample management solutions and genomic services to the life sciences sector, reported results for its fiscal third quarter on Aug. 4.
Azenta, formerly the life sciences division of Brooks Automation before the semiconductor business was spun off, competes with larger life sciences tools providers including Thermo Fisher Scientific and Danaher in the sample management and genomics services market. The company has not yet disclosed segment-level revenue breakdowns, year-over-year comparisons, or forward guidance for the remainder of fiscal 2026.
The EPS beat of 37.8 percent over consensus reflects stronger-than-expected profitability in the quarter. Azenta's sample management business serves pharmaceutical, biotech, and academic research customers, while its genomics services arm provides sequencing and gene synthesis solutions. The company has been investing in expanding its automated sample storage capacity and genomic services offerings to capture growing demand from drug discovery and clinical research programs.
The revenue beat of $8.9 million over consensus suggests the company's core sample management franchise continues to execute well, even as the broader life sciences tools market faces mixed demand conditions across different end markets. Pharmaceutical and biotech customers have maintained steady spending on research infrastructure, supporting demand for Azenta's automated storage systems and related consumables.
The beat comes as the broader life sciences tools sector continues to benefit from sustained research and development spending across pharmaceutical and biotechnology companies. Investors will watch the earnings call for management commentary on order momentum, pricing trends, and whether the company raises its full-year outlook. Azenta shares trade on the Nasdaq under the ticker AZTA.
This article is for informational purposes only and does not constitute investment advice.
